Clinical Trials Logo

Peripheral T-cell Lymphoma clinical trials

View clinical trials related to Peripheral T-cell Lymphoma.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT04470141 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Start date: August 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.

NCT ID: NCT04457830 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of F520 for the treatment of relapsed and refractory peripheral T cell lymphoma (PTCL), and to evaluate the immunogenicity of F520.

NCT ID: NCT04052659 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Start date: April 15, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, single-center Phase II clinical trial for patients with relapsed or refractory Peripheral T-cell lymphoma (PTCL). Immunotherapy with anti-PD-1 antibodies, such as sintilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chidamide and azacitidine may respectively stop the growth of tumor cells by blocking histone deacetylation and DNA methylation enzymes needed for cell growth. Giving chidamide and azacitidine with sintilimab these three drugs may work better than single drug or combination of two drugs in treating patients with relapsed or refractory peripheral T-cell lymphoma.

NCT ID: NCT03553537 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: June 2018
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL).

NCT ID: NCT03023358 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Start date: February 2017
Phase: Phase 3
Study type: Interventional

The prognosis for Peripheral T cell lymphomas (PTCL) remains poor in comparison to B cell NHL. This is largely due to lower response rates and less durable responses to standard combination chemotherapy regimens such as CHOP. Whether CDOP plus Chidamide can improve the prognosis for PTCL.

NCT ID: NCT03000738 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.

NCT ID: NCT02856997 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.